Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 172

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 172
---
 prohibit us from manufacturing, importing, marketing or otherwise commercializing
our products and technology. In addition, if the breadth or strength of protection provided by the patents and patent applications we
own or in-license is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or
future technology or products. In addition, because of the substantial amount of discovery required in connection with intellectual property
litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.
There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities
analysts or investors view these announcements in a negative light, the price of our common stock could be adversely affected.

Lastly, we may
need to indemnify our customers, licensees, commercialization partners, and distributors with respect to infringement by our technology
or products of the intellectual property rights of third parties. Third parties may assert infringement claims against our customers,
licensees, commercialization partners, or distributors based on our technology or products. These claims may require us to initiate or
defend protracted and costly litigation on behalf of our customers, licensees, commercialization partners, or distributors, regardless
of the merits of these claims. If any of these third-party claims succeed or settle, we may be forced to pay damages or settlement payments
on behalf of our customers, licensees, commercialization partners, or distributors or may be required to obtain licenses for the technology
or products they use. If we cannot obtain all necessary licenses on commercially reasonable terms, our customers, licensees, commercialization
partners, or distributors may be forced to stop using or selling our products or technology.

Patents covering our technology
or products could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad.

The issuance
of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents or those we in-license may be
challenged in the courts or patent offices in the United States and abroad. We may be subject to a third-party pre-issuance submission
of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant and inter partes review,
or interference proceedings or other similar proceedings challenging our patent rights. An adverse determination in any such submission,
proceeding or litigation could reduce the scope